{"entity":{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","aka":[],"tldr":"Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer.","summary":"Jong-Mu Sun is a medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Lancet report of KEYNOTE-590, which showed that pembrolizumab plus cisplatin and fluorouracil improved overall survival compared with chemotherapy alone in untreated advanced oesophageal cancer, the basis for pembrolizumab's approval in this setting. He also runs thoracic oncology trials.","asOf":"2026-09-18","links":[],"tags":["oesophageal","immunotherapy","trialist"],"related":[],"cancers":["oesophageal-squamous-cell-carcinoma","oesophageal-adenocarcinoma","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-590-lancet-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Samsung Medical Center, Seoul","institutionId":"samsung-medical-center","specialisms":["Oesophageal cancer","Lung cancer","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sun%5BAuthor%5D"}],"papers":[]},"route":"/people/jong-mu-sun/","neighbours":{"cancer":[{"id":"oesophageal-adenocarcinoma","kind":"cancer","name":"Oesophageal and junctional adenocarcinoma","route":"/cancers/oesophageal-adenocarcinoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"}],"institution":[{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/"}],"paper":[{"id":"paper-keynote-590-lancet-2021","kind":"paper","name":"KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer","route":"/key-papers/paper-keynote-590-lancet-2021/"}]}}